A trio large pharmas traded units amid continued emphasis on narrowly focused portfolios. Novartis bought a pair of GSK cancer drugs to complement its Gleevec franchise, and in turn sold its vaccines business to GSK while also selling its animal health division to Lilly.
- See more at: http://healthandpharmainsight.tumblr.com/post/83842375761/in-case-you-missed-it#sthash.AjKFLjGO.dpuf
This is the most entertainingly abrasive article you will read about 23andMe this week. TLDR version: 23andMe is either taking a very brave stand for personal gene testing or running the ?single dumbest regulatory strategy ever? in its dealings with FDA.
Why are companies like Forest and Eisai slashing R&D these days? A timely Deloitte/Reuters analysis finds that companies are actually doing fine at getting drugs to market, but R&D returns are sagging (due in part, one suspects, to higher R&D costs driven by the shift towards specialty biologics, along with tighter-fisted payers and pill-splitting patients).